Trial Outcomes & Findings for A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults (NCT NCT05089630)
NCT ID: NCT05089630
Last Updated: 2026-07-17
Results Overview
The assessed solicited administration site adverse events were erythema (injection site redness), pain and swelling.
COMPLETED
PHASE1/PHASE2
333 participants
Within 7 days post each dose (doses administered on Day 1, Day 61 and Day 181)
2026-07-17
Participant Flow
Out of 333 enrolled participants, only 329 participants started the study and were included in the Exposed Set.
Participant milestones
| Measure |
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Placebo Group
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
69
|
61
|
60
|
60
|
79
|
|
Overall Study
COMPLETED
|
44
|
38
|
37
|
43
|
44
|
|
Overall Study
NOT COMPLETED
|
25
|
23
|
23
|
17
|
35
|
Reasons for withdrawal
| Measure |
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Placebo Group
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
1
|
1
|
0
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
14
|
9
|
5
|
5
|
17
|
|
Overall Study
Withdrawal by Subject, Not Due to an Adverse Avent
|
7
|
2
|
5
|
4
|
6
|
|
Overall Study
Migrated/Moved from the Study Area
|
0
|
1
|
1
|
1
|
2
|
|
Overall Study
Temperature Excursion
|
0
|
1
|
1
|
0
|
0
|
|
Overall Study
Study Dose Not Administered
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Death Due to Road Traffic Accident
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Other
|
3
|
9
|
11
|
6
|
9
|
Baseline Characteristics
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
Baseline characteristics by cohort
| Measure |
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Total
n=329 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
34.9 YEARS
STANDARD_DEVIATION 9.6 • n=20 Participants
|
33.0 YEARS
STANDARD_DEVIATION 8.8 • n=20 Participants
|
35.0 YEARS
STANDARD_DEVIATION 8.9 • n=40 Participants
|
32.2 YEARS
STANDARD_DEVIATION 9.5 • n=5 Participants
|
36.9 YEARS
STANDARD_DEVIATION 8.5 • n=9 Participants
|
34.6 YEARS
STANDARD_DEVIATION 9.2 • n=6 Participants
|
|
Sex: Female, Male
Female
|
35 Participants
n=20 Participants
|
30 Participants
n=20 Participants
|
34 Participants
n=40 Participants
|
35 Participants
n=5 Participants
|
38 Participants
n=9 Participants
|
172 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
34 Participants
n=20 Participants
|
31 Participants
n=20 Participants
|
26 Participants
n=40 Participants
|
25 Participants
n=5 Participants
|
41 Participants
n=9 Participants
|
157 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
16 Participants
n=20 Participants
|
12 Participants
n=20 Participants
|
13 Participants
n=40 Participants
|
12 Participants
n=5 Participants
|
13 Participants
n=9 Participants
|
66 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=20 Participants
|
4 Participants
n=20 Participants
|
5 Participants
n=40 Participants
|
6 Participants
n=5 Participants
|
1 Participants
n=9 Participants
|
18 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=9 Participants
|
1 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
White
|
49 Participants
n=20 Participants
|
43 Participants
n=20 Participants
|
38 Participants
n=40 Participants
|
37 Participants
n=5 Participants
|
63 Participants
n=9 Participants
|
230 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
Missing
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=9 Participants
|
3 Participants
n=6 Participants
|
|
Race/Ethnicity, Customized
Other
|
1 Participants
n=20 Participants
|
2 Participants
n=20 Participants
|
4 Participants
n=40 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=9 Participants
|
11 Participants
n=6 Participants
|
PRIMARY outcome
Timeframe: Within 7 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Solicited Safety Set which included all participants who received at least 1 dose of the study intervention (Exposed Set) who have solicited safety data. Only the participants with solicited administration site adverse events data available at the specified time period were reported in this outcome measure.
The assessed solicited administration site adverse events were erythema (injection site redness), pain and swelling.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=68 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=59 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Erythema, Within 7 days from dosing at Day 61
|
1 Participants
|
4 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Erythema, Within 7 days from dosing at Day 181
|
1 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
0 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Pain, Within 7 days from dosing at Day 1
|
2 Participants
|
39 Participants
|
40 Participants
|
37 Participants
|
41 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Pain, Within 7 days from dosing at Day 61
|
2 Participants
|
37 Participants
|
38 Participants
|
39 Participants
|
39 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Pain, Within 7 days from dosing at Day 181
|
1 Participants
|
29 Participants
|
28 Participants
|
28 Participants
|
29 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Swelling, Within 7 days from dosing at Day 1
|
0 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Swelling, Within 7 days from dosing at Day 61
|
0 Participants
|
4 Participants
|
3 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Erythema, Within 7 days from dosing at Day 1
|
0 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Solicited Administration Site Adverse Events Post Each Dose Administration
Swelling, Within 7 days from dosing at Day 181
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Within 7 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Solicited Safety Set. Only the participants with solicited systemic adverse events data available at the specified timepoints were reported in this outcome measure.
The assessed solicited administration site adverse events were arthralgia, fatigue, headache, fever and myalgia. Fever was defined as body temperature ≥38.0°Celsius/100.4°Fahrenheit.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=68 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=59 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Myalgia, Within 7 days from dosing at Day 1
|
5 Participants
|
21 Participants
|
25 Participants
|
19 Participants
|
29 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Arthralgia, Within 7 days from dosing at Day 1
|
1 Participants
|
5 Participants
|
4 Participants
|
7 Participants
|
9 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Arthralgia, Within 7 days from dosing at Day 61
|
0 Participants
|
13 Participants
|
5 Participants
|
12 Participants
|
12 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Arthralgia, Within 7 days from dosing at Day 181
|
3 Participants
|
5 Participants
|
2 Participants
|
3 Participants
|
7 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fatigue, Within 7 days from dosing at Day 1
|
14 Participants
|
29 Participants
|
28 Participants
|
29 Participants
|
24 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fatigue, Within 7 days from dosing at Day 61
|
4 Participants
|
30 Participants
|
30 Participants
|
32 Participants
|
32 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fatigue, Within 7 days from dosing at Day 181
|
8 Participants
|
26 Participants
|
20 Participants
|
21 Participants
|
19 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fever, Within 7 days from dosing at Day 1
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fever, Within 7 days from dosing at Day 61
|
1 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Fever, Within 7 days from dosing at Day 181
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Headache, Within 7 days from dosing at Day 1
|
8 Participants
|
19 Participants
|
24 Participants
|
14 Participants
|
20 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Headache, Within 7 days from dosing at Day 61
|
5 Participants
|
22 Participants
|
25 Participants
|
22 Participants
|
22 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Headache, Within 7 days from dosing at Day 181
|
6 Participants
|
19 Participants
|
15 Participants
|
18 Participants
|
15 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Myalgia, Within 7 days from dosing at Day 61
|
3 Participants
|
29 Participants
|
25 Participants
|
25 Participants
|
33 Participants
|
|
Number of Participants With Solicited Systemic Adverse Events Post Each Dose Administration
Myalgia, Within 7 days from dosing at Day 181
|
1 Participants
|
19 Participants
|
11 Participants
|
11 Participants
|
24 Participants
|
PRIMARY outcome
Timeframe: Within 7 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Unsolicited Safety Set, which included all participants who received at least 1 dose of the study intervention (Exposed Set) that report unsolicited AEs/report not having unsolicited AEs. Only the participants with unsolicited AEs data available at the specified time period were reported in this outcome measure.
An unsolicited AE is defined as an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited AEs include both serious and non-serious AEs.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Unsolicited Adverse Events (AEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 1
|
4 Participants
|
4 Participants
|
8 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Unsolicited Adverse Events (AEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 61
|
3 Participants
|
9 Participants
|
7 Participants
|
4 Participants
|
5 Participants
|
|
Number of Participants With Unsolicited Adverse Events (AEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 181
|
1 Participants
|
5 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Within 7 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Unsolicited Safety Set. Only the participants with unsolicited SAEs data available at the specified time period were reported in this outcome measure.
An SAE is defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment. An unsolicited SAE is defined as an SAE that was not included in a list of solicited events using a Participant Diary.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Unsolicited Serious Adverse Events (SAEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Unsolicited Serious Adverse Events (SAEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 61
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Unsolicited Serious Adverse Events (SAEs) Within 7 Days Post Each Dose Administration
Within 7 days from dosing at Day 181
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Within 30 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Unsolicited Safety Set. Only the participants with unsolicited AEs data available at the specified time period were reported in this outcome measure.
An unsolicited AE is defined as an AE that was not included in a list of solicited events using a Participant Diary. The solicited AEs that had an onset after 7 days post each dose administration are considered unsolicited AEs. Unsolicited AEs include both serious and non-serious AEs.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Unsolicited AEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 181
|
5 Participants
|
12 Participants
|
5 Participants
|
7 Participants
|
5 Participants
|
|
Number of Participants With Unsolicited AEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 1
|
9 Participants
|
12 Participants
|
10 Participants
|
13 Participants
|
12 Participants
|
|
Number of Participants With Unsolicited AEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 61
|
7 Participants
|
13 Participants
|
9 Participants
|
8 Participants
|
8 Participants
|
PRIMARY outcome
Timeframe: Within 30 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Unsolicited Safety Set. Only the participants with unsolicited SAEs data available at the specified time period were reported in this outcome measure.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Unsolicited SAEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Unsolicited SAEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 61
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Unsolicited SAEs up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 181
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Within 30 days post each dose (doses administered on Day 1, Day 61 and Day 181)Population: The analysis was performed on the Unsolicited Safety Set. Only the participants with MAEs data available at the specified time period were reported in this outcome measure.
MAE is defined as an AE for which the participant received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (i.e., nurse practitioner or physician assistant or medical doctor) for any reason.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Medically Attended Events (MAEs) up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 1
|
3 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Medically Attended Events (MAEs) up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 61
|
3 Participants
|
3 Participants
|
3 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Medically Attended Events (MAEs) up to 30 Days Post Each Dose Administration
Within 30 days from dosing at Day 181
|
1 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
PRIMARY outcome
Timeframe: On Day 1Population: The analysis was performed on the Exposed set, which included all participants who received at least 1 dose of the study intervention. Only the participants with data available for the specified laboratory parameters at Day 1 were reported in this outcome measure.
The hematological and biochemical parameters included alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, white blood cells (WBC). Categories reported when comparing normal range and Day 1 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=78 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Eosinophils, Above
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Hemoglobin, Below
|
8 Participants
|
11 Participants
|
5 Participants
|
4 Participants
|
6 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
WBC, Within
|
74 Participants
|
68 Participants
|
56 Participants
|
58 Participants
|
57 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Lymphocytes, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Neutrophils, Within
|
74 Participants
|
68 Participants
|
54 Participants
|
56 Participants
|
57 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Hemoglobin, Above
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
WBC, Below
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
WBC, Above
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Lymphocytes, Within
|
77 Participants
|
68 Participants
|
59 Participants
|
59 Participants
|
57 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Neutrophils, Below
|
2 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Neutrophils, Above
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Platelets, Within
|
76 Participants
|
67 Participants
|
58 Participants
|
57 Participants
|
58 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Platelets, Above
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
ALT, Within
|
76 Participants
|
68 Participants
|
56 Participants
|
57 Participants
|
59 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
ALT, Above
|
1 Participants
|
1 Participants
|
5 Participants
|
3 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
ALT, Missing
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
AST, Within
|
76 Participants
|
68 Participants
|
57 Participants
|
59 Participants
|
59 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
AST, Above
|
2 Participants
|
1 Participants
|
4 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Creatinine, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Creatinine, Within
|
72 Participants
|
66 Participants
|
56 Participants
|
57 Participants
|
59 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Creatinine, Above
|
6 Participants
|
3 Participants
|
5 Participants
|
3 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Eosinophils, Below
|
5 Participants
|
5 Participants
|
5 Participants
|
5 Participants
|
5 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Eosinophils, Within
|
71 Participants
|
62 Participants
|
54 Participants
|
54 Participants
|
54 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 1
Hemoglobin, Within
|
69 Participants
|
56 Participants
|
54 Participants
|
55 Participants
|
54 Participants
|
PRIMARY outcome
Timeframe: On Day 8Population: The analysis was performed on the Exposed set. Only the participants with data available for the specified laboratory parameters at Day 8 were reported in this outcome measure.
The hematological and biochemical parameters included ALT, AST, creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, WBC. Categories reported when comparing normal range and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=69 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=67 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=59 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=54 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=56 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Eosinophils, Within
|
63 Participants
|
63 Participants
|
56 Participants
|
53 Participants
|
49 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Eosinophils, Above
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Lymphocytes, Below
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
ALT, Within
|
64 Participants
|
64 Participants
|
56 Participants
|
51 Participants
|
54 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
ALT, Above
|
4 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
ALT, Missing
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
AST, Within
|
64 Participants
|
63 Participants
|
57 Participants
|
54 Participants
|
54 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
AST, Above
|
4 Participants
|
4 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Creatinine, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Creatinine, Within
|
64 Participants
|
60 Participants
|
54 Participants
|
46 Participants
|
52 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Creatinine, Above
|
5 Participants
|
7 Participants
|
5 Participants
|
8 Participants
|
4 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Eosinophils, Below
|
2 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
5 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Hemoglobin, Below
|
9 Participants
|
13 Participants
|
11 Participants
|
7 Participants
|
9 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Hemoglobin, Within
|
56 Participants
|
52 Participants
|
48 Participants
|
47 Participants
|
47 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Hemoglobin, Above
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
WBC, Below
|
2 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
WBC, Within
|
62 Participants
|
64 Participants
|
56 Participants
|
52 Participants
|
54 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
WBC, Above
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Lymphocytes, Within
|
65 Participants
|
65 Participants
|
58 Participants
|
53 Participants
|
55 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Neutrophils, Below
|
3 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Neutrophils, Within
|
61 Participants
|
64 Participants
|
55 Participants
|
52 Participants
|
54 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Neutrophils, Above
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Platelets, Within
|
64 Participants
|
65 Participants
|
55 Participants
|
52 Participants
|
53 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Platelets, Above
|
1 Participants
|
0 Participants
|
3 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 8
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: On Day 61Population: The analysis was performed on the Exposed set. Only the participants with data available for the specified laboratory parameters at Day 61 were reported in this outcome measure.
The hematological and biochemical parameters included ALT, AST, creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, WBC. Categories reported when comparing normal range and Day 61 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=69 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=62 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=53 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=55 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=52 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
ALT, Above
|
4 Participants
|
5 Participants
|
3 Participants
|
4 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
AST, Above
|
2 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Creatinine, Within
|
62 Participants
|
57 Participants
|
48 Participants
|
52 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Hemoglobin, Within
|
58 Participants
|
53 Participants
|
46 Participants
|
50 Participants
|
44 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Creatinine, Below
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Creatinine, Above
|
6 Participants
|
5 Participants
|
4 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
ALT, Within
|
65 Participants
|
57 Participants
|
50 Participants
|
51 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
ALT, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
AST, Within
|
67 Participants
|
60 Participants
|
52 Participants
|
54 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Eosinophils, Below
|
5 Participants
|
3 Participants
|
2 Participants
|
6 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Eosinophils, Within
|
60 Participants
|
58 Participants
|
51 Participants
|
45 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Eosinophils, Above
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Hemoglobin, Below
|
8 Participants
|
9 Participants
|
7 Participants
|
3 Participants
|
7 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Hemoglobin, Above
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
WBC, Below
|
2 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
WBC, Within
|
61 Participants
|
59 Participants
|
51 Participants
|
49 Participants
|
50 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
WBC, Above
|
3 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Lymphocytes, Below
|
0 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Lymphocytes, Within
|
66 Participants
|
59 Participants
|
52 Participants
|
53 Participants
|
49 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Neutrophils, Below
|
2 Participants
|
3 Participants
|
1 Participants
|
4 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Neutrophils, Within
|
61 Participants
|
59 Participants
|
52 Participants
|
49 Participants
|
50 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Neutrophils, Above
|
3 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Platelets, Within
|
65 Participants
|
62 Participants
|
52 Participants
|
51 Participants
|
49 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Platelets, Above
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 61
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: On Day 68Population: The analysis was performed on the Exposed set. Only the participants with data available for the specified laboratory parameters at Day 68 were reported in this outcome measure.
The hematological and biochemical parameters included ALT, AST, creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, WBC. Categories reported when comparing normal range and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=56 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=58 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=51 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=49 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=53 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
AST, Within
|
53 Participants
|
56 Participants
|
50 Participants
|
47 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Creatinine, Within
|
49 Participants
|
52 Participants
|
47 Participants
|
44 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Hemoglobin, Within
|
44 Participants
|
46 Participants
|
39 Participants
|
43 Participants
|
41 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Hemoglobin, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
WBC, Below
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
WBC, Within
|
53 Participants
|
57 Participants
|
49 Participants
|
48 Participants
|
52 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
WBC, Above
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Lymphocytes, Below
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Lymphocytes, Within
|
53 Participants
|
57 Participants
|
50 Participants
|
49 Participants
|
53 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Neutrophils, Below
|
1 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Neutrophils, Within
|
53 Participants
|
57 Participants
|
47 Participants
|
47 Participants
|
52 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Neutrophils, Above
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Platelets, Within
|
54 Participants
|
58 Participants
|
47 Participants
|
46 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Platelets, Above
|
0 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
ALT, Within
|
51 Participants
|
53 Participants
|
47 Participants
|
44 Participants
|
51 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
ALT, Above
|
5 Participants
|
5 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
ALT, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
AST, Above
|
3 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Creatinine, Below
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Creatinine, Above
|
6 Participants
|
6 Participants
|
4 Participants
|
5 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Eosinophils, Below
|
2 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Eosinophils, Within
|
50 Participants
|
53 Participants
|
51 Participants
|
48 Participants
|
50 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Eosinophils, Above
|
2 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 68
Hemoglobin, Below
|
10 Participants
|
12 Participants
|
12 Participants
|
6 Participants
|
12 Participants
|
PRIMARY outcome
Timeframe: On Day 181Population: The analysis was performed on the Exposed Set. Only the participants with data available for the specified laboratory parameters at Day 181 were reported in this outcome measure.
The hematological and biochemical parameters included ALT, AST, creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, WBC. Categories reported when comparing normal range and Day 181 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=55 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=54 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=45 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=48 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=50 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Creatinine, Below
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
WBC, Below
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
ALT, Within
|
50 Participants
|
52 Participants
|
44 Participants
|
44 Participants
|
46 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
ALT, Above
|
5 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
ALT, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
AST, Within
|
53 Participants
|
52 Participants
|
45 Participants
|
47 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
AST, Above
|
2 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Creatinine, Within
|
46 Participants
|
48 Participants
|
45 Participants
|
44 Participants
|
46 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Creatinine, Above
|
8 Participants
|
6 Participants
|
0 Participants
|
4 Participants
|
3 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Eosinophils, Below
|
1 Participants
|
5 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Eosinophils, Within
|
52 Participants
|
47 Participants
|
39 Participants
|
41 Participants
|
44 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Eosinophils, Above
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Hemoglobin, Below
|
7 Participants
|
7 Participants
|
6 Participants
|
3 Participants
|
7 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Hemoglobin, Within
|
47 Participants
|
46 Participants
|
37 Participants
|
42 Participants
|
40 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Hemoglobin, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
WBC, Within
|
53 Participants
|
52 Participants
|
42 Participants
|
43 Participants
|
45 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
WBC, Above
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Lymphocytes, Below
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Lymphocytes, Within
|
54 Participants
|
52 Participants
|
42 Participants
|
45 Participants
|
47 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Neutrophils, Below
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Neutrophils, Within
|
54 Participants
|
52 Participants
|
41 Participants
|
42 Participants
|
46 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Neutrophils, Above
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Platelets, Within
|
54 Participants
|
53 Participants
|
42 Participants
|
45 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Platelets, Above
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 181
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: On Day 188Population: The analysis was performed on the Exposed Set. Only the participants with data available for the specified laboratory parameters at Day 188 were reported in this outcome measure.
The hematological and biochemical parameters included ALT, AST, creatinine, eosinophils, hemoglobin, lymphocytes, neutrophils, platelets, WBC. Categories reported when comparing normal range and Day 188 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at timing\> (e.g. Hemoglobin, Below). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Missing = No results are available for the corresponding laboratory parameter at the specific timepoint.
Outcome measures
| Measure |
Placebo Group
n=50 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=52 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=41 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=44 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=49 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Platelets, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Platelets, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
ALT, Within
|
47 Participants
|
48 Participants
|
39 Participants
|
41 Participants
|
49 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
ALT, Above
|
3 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Creatinine, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Eosinophils, Below
|
2 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
ALT, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
AST, Within
|
49 Participants
|
50 Participants
|
40 Participants
|
42 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
AST, Above
|
1 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
AST, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Creatinine, Within
|
43 Participants
|
46 Participants
|
37 Participants
|
35 Participants
|
45 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Creatinine, Above
|
7 Participants
|
6 Participants
|
4 Participants
|
9 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Creatinine, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Eosinophils, Within
|
47 Participants
|
45 Participants
|
39 Participants
|
40 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Eosinophils, Above
|
1 Participants
|
3 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Eosinophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Hemoglobin, Below
|
7 Participants
|
6 Participants
|
6 Participants
|
9 Participants
|
7 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Hemoglobin, Within
|
43 Participants
|
44 Participants
|
35 Participants
|
35 Participants
|
42 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Hemoglobin, Above
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Hemoglobin, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
WBC, Below
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
WBC, Within
|
48 Participants
|
47 Participants
|
40 Participants
|
42 Participants
|
47 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
WBC, Above
|
2 Participants
|
3 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
WBC, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Lymphocytes, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Lymphocytes, Within
|
50 Participants
|
50 Participants
|
39 Participants
|
43 Participants
|
48 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Lymphocytes, Above
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Lymphocytes, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Neutrophils, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Neutrophils, Within
|
50 Participants
|
48 Participants
|
40 Participants
|
43 Participants
|
47 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Neutrophils, Above
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Neutrophils, Missing
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Platelets, Below
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Hematological and Biochemical Laboratory Abnormalities on Day 188
Platelets, Within
|
50 Participants
|
50 Participants
|
41 Participants
|
40 Participants
|
49 Participants
|
SECONDARY outcome
Timeframe: Day 1 to Day 546Population: The analysis was performed on the unsolicited Safety Set. Only the participants with any unsolicited adverse events, SAEs, MAEs and pIMDs data available at the specified time period were reported in this outcome measure.
Unsolicited AE=AE that was not included in a list of solicited events using a Participant Diary; the solicited AEs that had an onset after 7 days post each dose administration are considered unsolicited AEs; both serious and non-serious AEs are included. SAE=any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment. MAE=AE for which the participant received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (i.e., nurse practitioner or physician assistant or medical doctor) for any reason. pIMDs=a subset of adverse events that include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune etiology.
Outcome measures
| Measure |
Placebo Group
n=79 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Number of Participants With Unsolicited Events, SAEs, MAEs and Potential Immune Mediated Diseases (pIMDs) From Day 1 to Day 546 (End of Study)
SAEs
|
2 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Unsolicited Events, SAEs, MAEs and Potential Immune Mediated Diseases (pIMDs) From Day 1 to Day 546 (End of Study)
MAEs
|
12 Participants
|
13 Participants
|
15 Participants
|
19 Participants
|
17 Participants
|
|
Number of Participants With Unsolicited Events, SAEs, MAEs and Potential Immune Mediated Diseases (pIMDs) From Day 1 to Day 546 (End of Study)
pIMDs
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Unsolicited Events, SAEs, MAEs and Potential Immune Mediated Diseases (pIMDs) From Day 1 to Day 546 (End of Study)
Unsolicited AEs
|
31 Participants
|
37 Participants
|
27 Participants
|
34 Participants
|
30 Participants
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on Per-Protocol Set (PPS),which included participants who received all doses, had immunogenicity results, complied with dosing/blood draw intervals,without intercurrent conditions,without prohibited medication/vaccination. The analysis was done according to the intervention that participants received at Day 1. Only the participants with nAbs against epithelial cell infection (CMV serostatus: sero-positive) data available at the specified time points were reported here.
Neutralizing antibodies (nAbs) against epithelial cell infection were measured with neutralizing assay and the results were expressed as GMT.
Outcome measures
| Measure |
Placebo Group
n=41 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=12 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=9 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=8 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=13 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 31
|
2349.7 Titer
Interval 1865.9 to 2958.8
|
18046.5 Titer
Interval 12885.5 to 25274.5
|
15947.5 Titer
Interval 11118.0 to 22874.8
|
19324.1 Titer
Interval 13258.7 to 28164.1
|
21342.4 Titer
Interval 16385.6 to 27798.7
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 1
|
2594.2 Titer
Interval 2055.2 to 3274.6
|
2088.2 Titer
Interval 1234.4 to 3532.5
|
1957.2 Titer
Interval 1371.1 to 2793.7
|
2108.2 Titer
Interval 949.1 to 4683.1
|
1683.1 Titer
Interval 1044.9 to 2711.2
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 61
|
2437.4 Titer
Interval 1817.7 to 3268.4
|
16783.4 Titer
Interval 10958.5 to 25704.7
|
13982.2 Titer
Interval 9479.4 to 20623.9
|
17609.0 Titer
Interval 9756.5 to 31781.5
|
19393.7 Titer
Interval 14640.9 to 25689.4
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 91
|
2182.4 Titer
Interval 1648.9 to 2888.6
|
12489.0 Titer
Interval 6822.0 to 22863.3
|
11146.9 Titer
Interval 7187.3 to 17288.1
|
15414.4 Titer
Interval 8835.6 to 26891.7
|
15676.6 Titer
Interval 11712.3 to 20982.6
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 181
|
2236.0 Titer
Interval 1619.0 to 3088.1
|
13925.9 Titer
Interval 8112.5 to 23905.4
|
7431.6 Titer
Interval 4550.5 to 12136.7
|
16663.2 Titer
Interval 9413.9 to 29495.1
|
12040.3 Titer
Interval 7912.7 to 18321.0
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 211
|
2758.5 Titer
Interval 2003.6 to 3797.9
|
12839.0 Titer
Interval 5484.5 to 30055.5
|
8918.6 Titer
Interval 5285.3 to 15049.5
|
16645.8 Titer
Interval 10020.5 to 27651.6
|
13744.1 Titer
Interval 8248.3 to 22901.9
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 361
|
2039.6 Titer
Interval 1489.8 to 2792.3
|
14764.6 Titer
Interval 4612.4 to 47262.6
|
5267.0 Titer
Interval 3313.8 to 8371.3
|
11062.1 Titer
Interval 3954.3 to 30946.6
|
9898.5 Titer
Interval 6425.7 to 15248.0
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies (nAbs) Against Epithelial Cell Infection (CMV Status: Sero-positive)
Baseline CMV sero-positive, Day 546
|
2409.3 Titer
Interval 1844.9 to 3146.3
|
10935.2 Titer
Interval 3900.2 to 30659.8
|
6250.0 Titer
Interval 4063.7 to 9612.6
|
7370.4 Titer
Interval 1470.2 to 36950.0
|
8416.0 Titer
Interval 4937.6 to 14345.0
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on the PPS. The analysis was done according to the study intervention that participants received at Day 1. Only the participants with nAbs against epithelial cell infection (CMV serostatus: sero-negative) data available at the specified time points were reported in this outcome measure.
Outcome measures
| Measure |
Placebo Group
n=30 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=47 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=43 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=45 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=42 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 181
|
81.7 Titer
Interval 51.7 to 129.0
|
1336.9 Titer
Interval 977.6 to 1828.1
|
2242.6 Titer
Interval 1464.9 to 3433.2
|
1550.1 Titer
Interval 1112.7 to 2159.4
|
1693.8 Titer
Interval 1222.1 to 2347.4
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 211
|
78.2 Titer
Interval 48.7 to 125.4
|
8207.8 Titer
Interval 6945.7 to 9699.3
|
9089.4 Titer
Interval 6883.7 to 12001.9
|
5848.5 Titer
Interval 4690.5 to 7292.2
|
7285.0 Titer
Interval 5930.8 to 8948.3
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 361
|
114.4 Titer
Interval 60.0 to 218.1
|
2398.1 Titer
Interval 1832.3 to 3138.5
|
3017.0 Titer
Interval 2201.7 to 4134.2
|
1649.4 Titer
Interval 1110.5 to 2449.9
|
1696.6 Titer
Interval 1146.1 to 2511.5
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 546
|
88.9 Titer
Interval 49.6 to 159.3
|
1550.6 Titer
Interval 1193.7 to 2014.3
|
1896.8 Titer
Interval 1360.7 to 2644.1
|
1326.3 Titer
Interval 960.7 to 1831.0
|
1308.5 Titer
Interval 967.3 to 1770.1
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 31
|
72.5 Titer
Interval 51.4 to 102.5
|
191.3 Titer
Interval 131.4 to 278.5
|
279.2 Titer
Interval 175.7 to 443.7
|
155.5 Titer
Interval 108.6 to 222.6
|
252.5 Titer
Interval 171.8 to 371.1
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 91
|
59.5 Titer
Interval 59.5 to 59.5
|
4743.6 Titer
Interval 3510.8 to 6409.4
|
7831.9 Titer
Interval 5609.7 to 10934.3
|
4485.5 Titer
Interval 3219.3 to 6249.7
|
5150.2 Titer
Interval 4009.3 to 6615.8
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 61
|
62.8 Titer
Interval 58.1 to 68.0
|
141.4 Titer
Interval 95.0 to 210.6
|
201.1 Titer
Interval 118.9 to 340.3
|
127.0 Titer
Interval 87.8 to 183.6
|
167.5 Titer
Interval 111.5 to 251.6
|
|
GMT of nAbs Against Epithelial Cell Infection (CMV Status: Sero-negative)
Baseline CMV sero-negative, Day 1
|
68.5 Titer
Interval 51.4 to 91.2
|
67.6 Titer
Interval 56.4 to 81.0
|
62.7 Titer
Interval 56.4 to 69.9
|
61.4 Titer
Interval 57.6 to 65.4
|
65.5 Titer
Interval 54.0 to 79.4
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on the PPS. Only the participants with anti-pentamer IgG (CMV serostatus: seropositive) data available at the specified time points were reported in this outcome measure.
The vaccine-induced humoral immunity was quantified by measuring the concentration of the anti-pentamer by enzyme-linked immunosorbent assay (ELISA).
Outcome measures
| Measure |
Placebo Group
n=41 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=12 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=9 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=8 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=13 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 1
|
5955.3 ELISA units per milliliter (EU/mL)
Interval 4680.0 to 7578.1
|
4162.4 ELISA units per milliliter (EU/mL)
Interval 2514.0 to 6891.5
|
4646.4 ELISA units per milliliter (EU/mL)
Interval 2682.4 to 8048.4
|
4415.3 ELISA units per milliliter (EU/mL)
Interval 1693.8 to 11509.7
|
3356.3 ELISA units per milliliter (EU/mL)
Interval 2085.6 to 5401.4
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 31
|
6405.5 ELISA units per milliliter (EU/mL)
Interval 4987.0 to 8227.6
|
63206.8 ELISA units per milliliter (EU/mL)
Interval 48896.4 to 81705.6
|
76136.0 ELISA units per milliliter (EU/mL)
Interval 69483.5 to 83425.5
|
70053.1 ELISA units per milliliter (EU/mL)
Interval 52026.6 to 94325.4
|
75963.4 ELISA units per milliliter (EU/mL)
Interval 70516.7 to 81830.8
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 61
|
5122.9 ELISA units per milliliter (EU/mL)
Interval 3866.5 to 6787.5
|
56100.2 ELISA units per milliliter (EU/mL)
Interval 32989.4 to 95401.2
|
61055.1 ELISA units per milliliter (EU/mL)
Interval 47694.3 to 78158.8
|
60309.2 ELISA units per milliliter (EU/mL)
Interval 32055.0 to 113467.5
|
69559.3 ELISA units per milliliter (EU/mL)
Interval 62320.3 to 77639.2
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 91
|
5378.7 ELISA units per milliliter (EU/mL)
Interval 4034.5 to 7170.8
|
52956.8 ELISA units per milliliter (EU/mL)
Interval 26623.7 to 105335.8
|
56759.7 ELISA units per milliliter (EU/mL)
Interval 44693.2 to 72083.9
|
69114.3 ELISA units per milliliter (EU/mL)
Interval 54301.6 to 87967.8
|
65006.2 ELISA units per milliliter (EU/mL)
Interval 55733.8 to 75821.3
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 181
|
2800.3 ELISA units per milliliter (EU/mL)
Interval 1408.0 to 5569.2
|
60978.8 ELISA units per milliliter (EU/mL)
Interval 26275.7 to 141515.2
|
40817.7 ELISA units per milliliter (EU/mL)
Interval 23675.7 to 70370.8
|
60500.5 ELISA units per milliliter (EU/mL)
Interval 40484.4 to 90412.8
|
13228.6 ELISA units per milliliter (EU/mL)
Interval 1561.4 to 112075.8
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 211
|
5707.8 ELISA units per milliliter (EU/mL)
Interval 3973.2 to 8199.7
|
61922.5 ELISA units per milliliter (EU/mL)
Interval 28018.8 to 136850.7
|
45090.5 ELISA units per milliliter (EU/mL)
Interval 27322.5 to 74413.0
|
64013.9 ELISA units per milliliter (EU/mL)
Interval 44918.5 to 91227.1
|
65791.3 ELISA units per milliliter (EU/mL)
Interval 56786.7 to 76223.8
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 361
|
4256.4 ELISA units per milliliter (EU/mL)
Interval 2607.6 to 6947.5
|
70275.0 ELISA units per milliliter (EU/mL)
Interval 41466.6 to 119097.5
|
25395.5 ELISA units per milliliter (EU/mL)
Interval 15173.0 to 42505.2
|
3675.9 ELISA units per milliliter (EU/mL)
Interval 26.5 to 510252.9
|
21439.5 ELISA units per milliliter (EU/mL)
Interval 4528.7 to 101498.0
|
|
Geometric Mean Concentration (GMC) of Anti-pentamer Immunoglobulin G (IgG) (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 546
|
5507.3 ELISA units per milliliter (EU/mL)
Interval 4226.8 to 7175.9
|
73801.2 ELISA units per milliliter (EU/mL)
Interval 60655.6 to 89795.9
|
22318.0 ELISA units per milliliter (EU/mL)
Interval 13478.9 to 36953.6
|
27775.9 ELISA units per milliliter (EU/mL)
Interval 6435.5 to 119881.1
|
30501.0 ELISA units per milliliter (EU/mL)
Interval 20218.3 to 46013.4
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on the PPS. Only the participants with anti-pentamer IgG (CMV serostatus: sero-negative) data available at the specified time points were reported in this outcome measure.
Outcome measures
| Measure |
Placebo Group
n=30 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=47 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=43 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=45 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=42 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 91
|
47.5 ELISA units per milliliter (EU/mL)
Interval 47.5 to 47.5
|
66744.1 ELISA units per milliliter (EU/mL)
Interval 58610.1 to 76007.0
|
70244.9 ELISA units per milliliter (EU/mL)
Interval 58431.0 to 84447.3
|
51455.6 ELISA units per milliliter (EU/mL)
Interval 32470.0 to 81542.2
|
69461.5 ELISA units per milliliter (EU/mL)
Interval 63415.7 to 76083.6
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 181
|
55.7 ELISA units per milliliter (EU/mL)
Interval 40.1 to 77.4
|
19362.4 ELISA units per milliliter (EU/mL)
Interval 15121.9 to 24792.1
|
19634.4 ELISA units per milliliter (EU/mL)
Interval 11567.7 to 33326.6
|
10273.3 ELISA units per milliliter (EU/mL)
Interval 5119.0 to 20617.8
|
14505.2 ELISA units per milliliter (EU/mL)
Interval 9273.2 to 22689.2
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 211
|
57.3 ELISA units per milliliter (EU/mL)
Interval 38.8 to 84.5
|
55233.1 ELISA units per milliliter (EU/mL)
Interval 48376.1 to 63062.0
|
60289.8 ELISA units per milliliter (EU/mL)
Interval 50895.1 to 71418.7
|
17170.6 ELISA units per milliliter (EU/mL)
Interval 6741.2 to 43735.5
|
24218.4 ELISA units per milliliter (EU/mL)
Interval 10137.9 to 57855.3
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 361
|
47.5 ELISA units per milliliter (EU/mL)
Interval 47.5 to 47.5
|
19123.4 ELISA units per milliliter (EU/mL)
Interval 15704.0 to 23287.5
|
13379.6 ELISA units per milliliter (EU/mL)
Interval 6989.0 to 25613.7
|
17229.0 ELISA units per milliliter (EU/mL)
Interval 13799.9 to 21510.3
|
17149.4 ELISA units per milliliter (EU/mL)
Interval 13631.3 to 21575.4
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 546
|
75.2 ELISA units per milliliter (EU/mL)
Interval 38.7 to 146.1
|
10525.2 ELISA units per milliliter (EU/mL)
Interval 8332.4 to 13295.2
|
12054.1 ELISA units per milliliter (EU/mL)
Interval 9028.6 to 16093.4
|
8678.1 ELISA units per milliliter (EU/mL)
Interval 6671.2 to 11288.7
|
9490.6 ELISA units per milliliter (EU/mL)
Interval 7421.7 to 12136.4
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 1
|
54.4 ELISA units per milliliter (EU/mL)
Interval 41.2 to 71.7
|
55.8 ELISA units per milliliter (EU/mL)
Interval 44.4 to 70.3
|
52.8 ELISA units per milliliter (EU/mL)
Interval 45.1 to 61.7
|
53.3 ELISA units per milliliter (EU/mL)
Interval 45.8 to 62.1
|
52.9 ELISA units per milliliter (EU/mL)
Interval 42.6 to 65.7
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 31
|
55.4 ELISA units per milliliter (EU/mL)
Interval 42.5 to 72.2
|
3801.8 ELISA units per milliliter (EU/mL)
Interval 2577.6 to 5607.3
|
4912.6 ELISA units per milliliter (EU/mL)
Interval 3022.0 to 7986.0
|
3552.8 ELISA units per milliliter (EU/mL)
Interval 2631.7 to 4796.4
|
4184.6 ELISA units per milliliter (EU/mL)
Interval 2875.4 to 6090.0
|
|
GMC of Anti-pentamer IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 61
|
47.5 ELISA units per milliliter (EU/mL)
Interval 47.5 to 47.5
|
2312.8 ELISA units per milliliter (EU/mL)
Interval 1527.2 to 3502.4
|
2825.6 ELISA units per milliliter (EU/mL)
Interval 1666.2 to 4791.9
|
1957.5 ELISA units per milliliter (EU/mL)
Interval 1413.9 to 2710.1
|
2430.0 ELISA units per milliliter (EU/mL)
Interval 1531.3 to 3856.2
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on the PPS. Only the participants with anti-gB IgG (CMV serostatus: sero-positive) data available at the specified time points were reported in this outcome measure.
The vaccine-induced humoral immunity was quantified by measuring the concentration of the anti-gB IgG binding antibodies by ELISA.
Outcome measures
| Measure |
Placebo Group
n=41 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=12 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=9 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=8 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=13 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 1
|
21199.1 EU/mL
Interval 17495.5 to 25686.7
|
16807.2 EU/mL
Interval 9740.9 to 28999.8
|
14677.4 EU/mL
Interval 8313.5 to 25913.1
|
20120.7 EU/mL
Interval 9509.5 to 42572.1
|
16221.5 EU/mL
Interval 10271.5 to 25618.0
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 31
|
18257.1 EU/mL
Interval 15052.4 to 22144.1
|
66740.2 EU/mL
Interval 46249.9 to 96308.3
|
69713.1 EU/mL
Interval 52294.9 to 92932.8
|
109132.0 EU/mL
Interval 53451.6 to 222814.6
|
75579.9 EU/mL
Interval 51122.6 to 111737.6
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 61
|
16443.7 EU/mL
Interval 12861.7 to 21023.3
|
58273.9 EU/mL
Interval 34831.0 to 97495.0
|
48404.7 EU/mL
Interval 35588.2 to 65836.8
|
91039.0 EU/mL
Interval 32744.9 to 253111.6
|
53782.6 EU/mL
Interval 38766.2 to 74615.6
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 91
|
15985.6 EU/mL
Interval 12566.4 to 20335.1
|
53127.7 EU/mL
Interval 26680.1 to 105792.5
|
62024.7 EU/mL
Interval 37691.3 to 102067.7
|
88624.7 EU/mL
Interval 42041.2 to 186824.8
|
62028.8 EU/mL
Interval 43352.1 to 88751.7
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 181
|
15348.4 EU/mL
Interval 11822.3 to 19926.2
|
44748.5 EU/mL
Interval 17636.2 to 113541.0
|
37511.5 EU/mL
Interval 23630.5 to 59546.2
|
67095.8 EU/mL
Interval 30105.2 to 149537.2
|
49659.4 EU/mL
Interval 32576.5 to 75700.7
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 211
|
18067.2 EU/mL
Interval 13697.6 to 23830.7
|
75673.6 EU/mL
Interval 33600.3 to 170429.8
|
50995.3 EU/mL
Interval 36520.7 to 71206.7
|
87492.4 EU/mL
Interval 41876.8 to 182796.1
|
66691.8 EU/mL
Interval 46959.4 to 94715.8
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 361
|
16143.7 EU/mL
Interval 12395.5 to 21025.3
|
41336.4 EU/mL
Interval 11371.3 to 150263.9
|
25672.0 EU/mL
Interval 16619.1 to 39656.3
|
46282.5 EU/mL
Interval 17872.4 to 119853.8
|
42016.5 EU/mL
Interval 27743.1 to 63633.2
|
|
GMC of Anti-glycoprotein B (gB) IgG (CMV Serostaus: Sero-positive)
Baseline CMV sero-positive, Day 546
|
18446.5 EU/mL
Interval 14655.6 to 23218.0
|
39486.4 EU/mL
Interval 8878.6 to 175610.6
|
29253.1 EU/mL
Interval 17866.2 to 47897.4
|
28078.7 EU/mL
Interval 4686.8 to 168221.4
|
25090.5 EU/mL
Interval 15797.9 to 39848.9
|
SECONDARY outcome
Timeframe: On Day 1, Day 31, Day 61, Day 91, Day 181, Day 211, Day 361 and Day 546Population: The analysis was performed on the PPS. Only the participants with anti-gB IgG (CMV serostatus: sero-negative) data available at the specified time points were reported in this outcome measure.
Outcome measures
| Measure |
Placebo Group
n=30 Participants
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=47 Participants
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=43 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=45 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=42 Participants
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 211
|
138.2 EU/mL
Interval 78.0 to 244.6
|
41716.8 EU/mL
Interval 33282.1 to 52289.2
|
38078.9 EU/mL
Interval 28547.2 to 50793.2
|
41517.5 EU/mL
Interval 33542.7 to 51388.5
|
33650.3 EU/mL
Interval 26408.3 to 42878.1
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 361
|
113.7 EU/mL
Interval 75.2 to 171.9
|
14449.2 EU/mL
Interval 11224.6 to 18600.1
|
12622.8 EU/mL
Interval 9090.0 to 17528.6
|
15316.6 EU/mL
Interval 12029.6 to 19501.8
|
8469.1 EU/mL
Interval 6491.5 to 11049.1
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 546
|
190.3 EU/mL
Interval 76.6 to 472.5
|
8577.8 EU/mL
Interval 6400.7 to 11495.5
|
7258.8 EU/mL
Interval 5030.1 to 10475.0
|
8975.2 EU/mL
Interval 6742.6 to 11947.2
|
5066.8 EU/mL
Interval 3908.4 to 6568.5
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 181
|
132.9 EU/mL
Interval 79.1 to 223.2
|
10447.1 EU/mL
Interval 7843.8 to 13914.6
|
10571.4 EU/mL
Interval 7042.6 to 15868.4
|
15910.9 EU/mL
Interval 12022.6 to 21056.5
|
7623.1 EU/mL
Interval 5559.4 to 10452.7
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 1
|
113.8 EU/mL
Interval 75.7 to 171.3
|
102.5 EU/mL
Interval 81.0 to 129.8
|
114.4 EU/mL
Interval 88.7 to 147.7
|
93.1 EU/mL
Interval 80.3 to 107.9
|
101.7 EU/mL
Interval 78.3 to 132.1
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 31
|
114.0 EU/mL
Interval 76.0 to 170.9
|
6043.1 EU/mL
Interval 4257.1 to 8578.3
|
7071.6 EU/mL
Interval 4512.9 to 11080.9
|
10176.1 EU/mL
Interval 7768.5 to 13329.8
|
6067.3 EU/mL
Interval 4321.0 to 8519.2
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 61
|
97.0 EU/mL
Interval 74.7 to 126.1
|
4208.8 EU/mL
Interval 2785.6 to 6359.1
|
5081.6 EU/mL
Interval 2805.1 to 9205.9
|
7192.3 EU/mL
Interval 4952.9 to 10444.0
|
3864.8 EU/mL
Interval 2484.8 to 6011.2
|
|
GMC of Anti-gB IgG (CMV Serostatus: Sero-negative)
Baseline CMV sero-negative, Day 91
|
97.0 EU/mL
Interval 74.6 to 126.0
|
29126.7 EU/mL
Interval 21569.8 to 39331.0
|
26239.9 EU/mL
Interval 18732.0 to 36756.9
|
38193.4 EU/mL
Interval 28885.8 to 50500.1
|
22817.2 EU/mL
Interval 17650.9 to 29495.7
|
Adverse Events
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
Placebo Group
Serious adverse events
| Measure |
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 participants at risk
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Placebo Group
n=79 participants at risk
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
1.4%
1/69 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.3%
1/79 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Psychiatric disorders
Bipolar disorder
|
0.00%
0/69 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.6%
1/61 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.7%
1/60 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/69 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.3%
1/79 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Renal and urinary disorders
Nephrolithiasis
|
1.4%
1/69 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/69 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.7%
1/60 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
1.4%
1/69 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/69 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.7%
1/60 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
Other adverse events
| Measure |
Pentamer (Low Dose)/Glycoprotein B (gB) (Low Dose)/Adjuvant Group
n=69 participants at risk
Participants received a dose of the candidate cytomegalovirus (CMV) vaccine consisting of a combination of low dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Low Dose)/Adjuvant Group
n=61 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and low dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (Medium Dose)/gB (Medium Dose)/Adjuvant Group
n=60 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of medium dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Pentamer (High Dose)/gB (Medium Dose)/Adjuvant Group
n=60 participants at risk
Participants received a dose of the candidate CMV vaccine consisting of a combination of high dose of pentamer and medium dose of gB antigens, adjuvanted, at Day 1, Day 61 and Day 181 intramuscularly.
|
Placebo Group
n=79 participants at risk
Participants received a dose of placebo at Day 1, Day 61 and Day 181 intramuscularly.
|
|---|---|---|---|---|---|
|
General disorders
Administration site pain
|
75.4%
52/69 • Number of events 52 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
77.0%
47/61 • Number of events 47 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
75.0%
45/60 • Number of events 45 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
78.3%
47/60 • Number of events 47 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
6.3%
5/79 • Number of events 5 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
General disorders
Fatigue
|
63.8%
44/69 • Number of events 44 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
77.0%
47/61 • Number of events 47 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
71.7%
43/60 • Number of events 43 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
65.0%
39/60 • Number of events 39 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
26.6%
21/79 • Number of events 21 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
General disorders
Administration site erythema
|
10.1%
7/69 • Number of events 7 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
9.8%
6/61 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
10.0%
6/60 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.0%
3/60 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.3%
1/79 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
General disorders
Administration site swelling
|
8.7%
6/69 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
11.5%
7/61 • Number of events 7 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.3%
2/60 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
10.0%
6/60 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
General disorders
Pyrexia
|
8.7%
6/69 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
8.2%
5/61 • Number of events 5 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.0%
3/60 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.0%
3/60 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
2.5%
2/79 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
General disorders
Injection site pruritus
|
5.8%
4/69 • Number of events 4 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.7%
1/60 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/79 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
58.0%
40/69 • Number of events 40 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
59.0%
36/61 • Number of events 36 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
55.0%
33/60 • Number of events 33 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
73.3%
44/60 • Number of events 44 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
7.6%
6/79 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
24.6%
17/69 • Number of events 17 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
14.8%
9/61 • Number of events 9 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
30.0%
18/60 • Number of events 18 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
30.0%
18/60 • Number of events 18 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.1%
4/79 • Number of events 4 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Nervous system disorders
Headache
|
53.6%
37/69 • Number of events 37 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
62.3%
38/61 • Number of events 38 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
53.3%
32/60 • Number of events 32 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
53.3%
32/60 • Number of events 32 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
20.3%
16/79 • Number of events 16 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Infections and infestations
COVID-19
|
5.8%
4/69 • Number of events 4 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
8.2%
5/61 • Number of events 5 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
10.0%
6/60 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.3%
2/60 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.8%
3/79 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Infections and infestations
Upper respiratory tract infection
|
8.7%
6/69 • Number of events 6 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.3%
2/61 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
6.7%
4/60 • Number of events 4 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
8.3%
5/60 • Number of events 5 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.8%
3/79 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Gastrointestinal disorders
Nausea
|
1.4%
1/69 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
4.9%
3/61 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.0%
3/60 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
8.3%
5/60 • Number of events 5 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.3%
1/79 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
2.9%
2/69 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
6.7%
4/60 • Number of events 4 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
1.7%
1/60 • Number of events 1 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
2.5%
2/79 • Number of events 2 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/69 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/61 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
0.00%
0/60 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
5.0%
3/60 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
3.8%
3/79 • Number of events 3 • Solicited events: within 7 days post-dose (doses administered on Day 1, Day 61 and Day 181); All-cause mortality, unsolicited AEs, SAEs, MAEs and pIMDs: from Day 1 to Day 546
Solicited and unsolicited adverse events were reported per participant, after any vaccination, for the assessed timeframe according to occurrence of each event. All events presented in the All-cause mortality, SAE and Other (not including Serious) AEs are reported for the Exposed set.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER